Strategic Management to Optimize Response To Cardiac Resynchronization Therapy
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 699 participants.
Also called NCT03089281
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 699 participants
- Sponsor
- Registry
-
NCT03089281
-
- Other papers using this trial's data
- Effects of Atrioventricular Optimization on Left Ventricular Reverse Remodeling With Cardiac Resynchronization Therapy: Results of the SMART-CRT Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, France, Germany, Ireland, Italy, Japan, Netherlands, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03089281. Randomized; double masking; primary purpose treatment. Start 2017-08-01 (actual); primary completion 2020-09-15 (actual). Results posted on 2022-04-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Strategic Management to Optimize Response To Cardiac Resynchronization Therapy
- Acronym
- SMART CRT
- Condition
- Heart Failure
- Intervention (Device)
- CRT-D
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct03089281- Content hash
edc298d419e7f1a5fd2c97f7a4a5457d77a44bec60f9fd5794f75b7ef6bd41d2